Kameel D. Farag - 16 Dec 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Interim CFO
Signature
/s/ Abizer Gaslightwala, as Attorney-in-Fact
Issuer symbol
AKTX
Transactions as of
16 Dec 2025
Net transactions value
+$9,999
Form type
4
Filing time
18 Dec 2025, 21:57:09 UTC
Previous filing
04 Nov 2025
Next filing
09 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Farag Kameel D. Interim CFO C/O AKARI THERAPEUTICS PLC, 401 EAST JACKSON STREET, SUITE 3300, TAMPA /s/ Abizer Gaslightwala, as Attorney-in-Fact 18 Dec 2025 0002093620

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTX Warrants to purchase American Depositary Shares ("ADRs") Purchase +24,745 24,745 16 Dec 2025 American Depositary Shares representing Ordinary Shares 24,745 $0.3883 Direct F1, F2, F3, F4
transaction AKTX Pre-Funded Warrants to purchase ADRs Purchase $9,999 +24,745 $0.4041 24,745 16 Dec 2025 American Depositary Shares representing Ordinary Shares 24,745 $0.000000 Direct F1, F2, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.
F2 On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 24,745 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 24,745 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.
F3 The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the Private Placement Unregistered Warrants remaining exercisable until fully exercised.
F4 The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.
F5 Conversion Exercise Price of Security is $0.00001